What Clinical Evaluation Steps And Patient Contraindications Should Practitioners Consider When Conducting Periorbital Aesthetic Treatments? Essential Safety Protocols For Optimal Outcomes.

Before any periorbital aesthetic treatment, practitioners should assess eyelid support, edema risk, skin condition, medical history, medications, and treatment-specific contraindications. The lower-eyelid snap test is essential before deep suborbital procedures, while patients with spontaneous edema, active infection, pregnancy, impaired wound healing, or significant scarring risk may require postponement, medical clearance, an alternative treatment, or exclusion from treatment.

Periorbital skin has little tissue reserve and lies close to the eyelid sphincter, lymphatic drainage system, and globe. Patient selection must therefore be based on anatomy and medical risk—not solely on the cosmetic concern being treated.

Begin With a Structured Clinical Evaluation

Establish the treatment objective

Determine whether the primary concern is static rhytids, hyperdynamic crow’s feet, skin laxity, edema, pigmentation, volume loss, or protruding fat.

Static wrinkles may respond to resurfacing, whereas hyperdynamic crow’s feet generally require assessment for neuromodulation rather than aggressive laser ablation. Selecting the wrong modality can produce limited improvement while increasing risk.

Review medical and dermatological history

Ask about previous eyelid or facial surgery, radiation exposure, autoimmune or connective-tissue disease, eczema, psoriasis, scleroderma, active cancer, uncontrolled systemic illness, photosensitivity, and prior abnormal scarring.

The history should also include recent oral isotretinoin use, recurrent herpes simplex, active medications, pregnancy or breastfeeding, and any condition that could impair healing or increase bruising.

Inspect the periorbital tissues

Evaluate skin quality, photodamage, hydration, laxity, rhytid pattern, pigmentation, scars, inflammation, lesions, and asymmetry.

Look specifically for pre-existing lower-eyelid fullness or intermittent swelling. Treatment that adds inflammation or volume may make this appearance more pronounced.

Assess Lower-Eyelid Structural Risk

Perform the snap test

The lower-eyelid snap test evaluates elastic recoil after gently pulling the eyelid away from the globe and releasing it.

Delayed recoil or a positive snap test indicates eyelid laxity. These patients are at increased risk of ectropion, lagophthalmos, and incomplete orbicularis sphincter function after aggressive or deep suborbital treatment.

Modify or avoid deep treatment when laxity is present

A positive snap test makes deep suborbital injections and intensive suborbital procedures unsuitable or higher risk.

The appropriate response may be treatment modification, referral for specialist assessment, or selection of a less invasive option rather than proceeding with the planned technique.

Screen for functional ocular concerns

Assess for symptoms such as dry eye, incomplete closure, excessive tearing, ocular irritation, and visual complaints. A history of eyelid malposition or prior periocular surgery should prompt additional caution and, where appropriate, ophthalmic evaluation.

Identify Edema and Lymphatic-Retention Risk

Ask about spontaneous swelling

Patients who regularly develop lower-eyelid swelling or retain lymphatic fluid are poor candidates for lower-eyelid injections and intensive suborbital procedures.

The concern is not merely temporary post-treatment swelling. These interventions can accentuate persistent or recurrent lower-eyelid fullness.

Distinguish edema from structural fullness

Determine whether fullness is caused primarily by fluid retention, fat prolapse, skin laxity, or injected volume.

This distinction matters because a treatment that improves skin texture may not correct orbital fat or edema, and an injection may worsen the appearance of a fluid-prone lower eyelid.

Evaluate Skin and Healing Risk Before Laser Treatment

Screen for active skin disease

Do not treat through active infection, open wounds, localized inflammation, or active herpes simplex lesions.

Patients with active eczema, psoriasis, scleroderma, or other connective-tissue or autoimmune skin disease require careful medical assessment before resurfacing.

Review scarring and radiation history

A history of keloid or hypertrophic scarring increases concern for abnormal healing. Prior facial irradiation may also impair re-epithelialization and should be treated as a significant contraindication or reason for specialist clearance.

Review isotretinoin and photosensitivity

Recent oral isotretinoin use is a major concern before ablative resurfacing because of the potential for impaired re-epithelialization and abnormal scarring. The supplied references identify use within the preceding six months as a contraindication.

Also assess photosensitizing medications and a history of photosensitivity, which can increase the risk of burns, scarring, and pigmentary alteration with laser or other energy-based treatments.

Assess skin type and treatment intensity

Document Fitzpatrick skin phototype, photodamage, hydration, and the severity of rhytids or scars.

Ablative CO₂ resurfacing is generally more appropriate for selected patients with substantial static rhytids or deep atrophic scars. Milder concerns or patients with greater pigmentary risk may require a less aggressive modality.

Review General and Treatment-Specific Contraindications

Absolute or usual reasons to defer elective treatment

Elective periorbital procedures should generally be deferred in the presence of:

Active skin infection or localized inflammation
Open or compromised wound areas
Active herpes simplex lesions
Pregnancy or breastfeeding
Uncontrolled medical disease
Active malignancy or malignant lesions at the treatment site
Recent oral isotretinoin use when ablative laser is planned
High risk of severe scarring or impaired wound healing

The exact status of some conditions depends on the modality and the patient’s medical history, so medical clearance may be more appropriate than an automatic permanent exclusion.

Relative contraindications requiring clearance or modification

Use additional caution with:

Neuromuscular disorders
Medications that impair neuromuscular transmission
Autoimmune or connective-tissue disease
Prior radiation at the treatment site
Keloid or hypertrophic scarring history
Photosensitizing medications or photosensitivity
Implanted electrical devices when using modalities that may interfere with them
Epilepsy or other conditions relevant to the selected energy device

A device-specific risk assessment is necessary because a contraindication for one technology may not apply identically to another.

Manage Bruising and Medication Risk

Review platelet-inhibiting drugs

Aspirin and NSAIDs can increase bruising and localized swelling around the delicate eye area.

The primary reference recommends discontinuation 7–14 days before treatment when medically safe, but practitioners should not instruct patients to stop prescribed antiplatelet or anticoagulant therapy independently. The prescribing clinician must determine whether interruption is appropriate.

Document all relevant medications

Record anticoagulants, antiplatelet drugs, photosensitizing medications, isotretinoin, immunosuppressants, and medications affecting neuromuscular transmission.

The decision should balance cosmetic bruising risk against the potentially serious medical risk of stopping an essential medication.

Conduct Modality-Specific Screening

For lower-eyelid injections

Prioritize the snap test, eyelid laxity assessment, edema history, skin quality, prior surgery, and expectations regarding lower-eyelid fullness.

Avoid or reconsider treatment in patients with delayed recoil or a strong tendency toward spontaneous edema.

For CO₂ or ablative resurfacing

Confirm the indication, skin type, photodamage, hydration, healing capacity, scarring history, radiation exposure, isotretinoin history, and absence of active infection or inflammation.

Ensure that the patient understands the required post-treatment care and the possibility of pigmentary changes, prolonged edema, or abnormal healing.

For non-invasive energy devices

Screen for pregnancy, active cancer, epilepsy, active infection, malignant lesions, photosensitizing medications, recent isotretinoin, and implanted electrical devices where relevant to the technology.

Energy settings and modality selection should be based on the patient’s tissue characteristics and risk profile rather than using a uniform protocol.

Confirm Expectations and Consent

Assess whether the goal is achievable

Explain what the selected procedure can and cannot correct. For example, resurfacing may improve static texture and rhytids but will not necessarily correct edema, orbital fat prolapse, or significant eyelid malposition.

Unrealistic expectations are a safety concern because they can lead to inappropriate treatment escalation or repeated procedures.

Document the decision

Record examination findings, the snap-test result, edema history, skin and medical history, medications, contraindications, treatment rationale, alternatives, and informed consent.

If a patient is unsuitable, the practitioner should explain the clinical reason transparently and recommend an appropriate alternative or referral rather than proceeding for financial reasons.

Understanding the Trade-offs

More aggressive treatment is not automatically better

Deeper injections and stronger resurfacing may offer greater correction for selected indications, but they also increase the consequences of poor patient selection.

Around the eyes, a modest treatment with an appropriate safety margin is often preferable to an aggressive treatment in a patient with laxity, edema, or impaired healing.

Avoid overgeneralizing contraindications

Not every risk factor is an absolute prohibition for every modality. The correct decision depends on the procedure, energy or injection depth, treatment site, patient health, and availability of medical oversight.

When uncertainty exists, postponement and specialist consultation are safer than relying on a generic protocol.

Do not compromise medication safety

Reducing bruising is not sufficient justification for stopping medically necessary antiplatelet or anticoagulant therapy.

Medication changes should be coordinated with the prescribing clinician and documented as part of the treatment plan.

How to Apply This to Clinical Practice

Use a standardized consultation and document the following before treatment:

If your primary focus is lower-eyelid injections: Perform the snap test, assess for eyelid laxity and spontaneous edema, and avoid deep treatment when recoil is delayed or swelling is prominent.
If your primary focus is CO₂ or ablative resurfacing: Review skin type, photodamage, healing capacity, scarring and radiation history, isotretinoin exposure, active skin disease, and realistic expectations.
If your primary focus is non-invasive energy treatment: Check modality-specific contraindications, including pregnancy, active infection, malignancy, implanted electrical devices, photosensitivity, epilepsy, and relevant medications.
If your primary focus is bruising prevention: Review aspirin, NSAIDs, antiplatelet, and anticoagulant use, but change prescribed therapy only with authorization from the treating medical clinician.
If your primary focus is overall patient safety: Defer treatment or obtain specialist clearance whenever anatomical or medical risk exceeds the expected cosmetic benefit.

Safe periorbital practice begins with disciplined patient selection, conservative treatment planning, and a willingness to decline procedures when the risk profile is unfavorable.

Summary Table:

Clinical Evaluation	Key Considerations	Contraindications
Medical History	Prior surgery, autoimmune disease, isotretinoin use	Active infection, pregnancy, uncontrolled illness
Lower-Eyelid Snap Test	Assess elastic recoil; delayed recoil indicates laxity	Positive test for deep procedures
Edema Risk	Spontaneous swelling or lymphatic retention	High risk for lower-eyelid injections
Skin Assessment	Fitzpatrick type, photodamage, scarring history	Active lesions, keloid history, recent radiation
Medication Review	Aspirin, NSAIDs, anticoagulants, photosensitizing drugs	Recent isotretinoin for ablative laser

Enhance your practice's safety and efficacy with BELIS's advanced aesthetic devices. Our professional-grade systems—including laser, IPL, and PDT platforms—are designed for clinics and premium salons. Contact us today to explore how our technology can support your patient care and business growth. Contact us now to learn more!

What clinical evaluation steps and patient contraindications should practitioners consider when conducting periorbital aesthetic treatments? Essential safety protocols for optimal outcomes.